Exciting advancements in Alzheimer\u2019s disease (AD) diagnostics are emerging, including a new blood test that could revolutionize early detection and disease monitoring. Here\u2019s what you need to know:
Key Developments:<\/p>\n\n\n\n
Blood-Based Biomarkers for Alzheimer\u2019s\nResearchers have identified specific proteins in the blood that correlate with Alzheimer\u2019s pathology, including:\nPhosphorylated Tau (p-tau217, p-tau181) \u2013 Strongly associated with amyloid and tau plaques in the brain.\nAmyloid Beta 42\/40 Ratio \u2013 Indicates amyloid buildup, a hallmark of AD.\nNeurofilament Light (NfL) \u2013 Marks neurodegeneration, showing disease progression.<\/code><\/pre>\n\n\n\nA 2024 study in JAMA Neurology found that a p-tau217 blood test could predict Alzheimer\u2019s with 89\u201396% accuracy, rivaling costly PET scans or invasive spinal taps.<\/p>\n\n\n\n
Tracking Disease Progression\nBlood tests may soon help determine how far Alzheimer\u2019s has advanced by measuring:\nEarly-stage (preclinical) AD \u2013 Elevated p-tau217 + abnormal amyloid.\nMild cognitive impairment (MCI) due to AD \u2013 Rising NfL + tau.\nLate-stage AD \u2013 Very high NfL + severe tau\/amyloid imbalance.\n\nAdvantages Over Current Methods\nFaster & Cheaper \u2013 Blood tests, like those for blood sugar or complete blood count, can cost around \u20b9500, while PET scans can range from \u20b910,000 to \u20b940,000+ depending on the type of scan and location.\nMore Accessible \u2013 Could be done in primary care settings, enabling earlier intervention.\nMonitoring Treatment Response \u2013 Useful for clinical trials and future anti-amyloid\/tau therapies (e.g., lecanemab, donanemab).<\/code><\/pre>\n\n\n\nCurrent Status & Challenges<\/p>\n\n\n\n
Not Yet FDA-Approved for Diagnosis \u2013 But companies (e.g., Quest Diagnostics, C2N Diagnostics) are rolling out commercially available tests (e.g., PrecivityAD2).\nFalse Positives\/Negatives Possible \u2013 Some non-AD dementias may show similar markers.\nStill Needs Validation \u2013 Larger, diverse population studies are ongoing.<\/code><\/pre>\n\n\n\nWhen Could This Be Available?<\/p>\n\n\n\n
Some tests (e.g., ALZpath p-tau217) are already used in research and select clinics.\nWidespread clinical use could happen in 2\u20135 years if validation succeeds.<\/code><\/pre>\n\n\n\nWhy This Matters<\/p>\n\n\n\n
Early detection could allow:
\u2714 Timely lifestyle interventions (diet, exercise, cognitive training).
\u2714 Eligibility for new anti-amyloid drugs (most effective in early stages).
\u2714 Better clinical trial recruitment for future therapies.<\/p>\n\n\n\n
Reference:<\/strong><\/p>\n\n\n\nhttps:\/\/www.mayoclinic.org\/diseases-conditions\/alzheimers-disease\/diagnosis-treatment\/drc-20350453<\/a><\/p>\n\n\n\nhttps:\/\/www.lunduniversity.lu.se\/article\/new-reliable-blood-marker-reveals-extent-alzheimers-pathology-brain<\/a><\/p>\n\n\n\nhttps:\/\/www.nih.gov\/news-events\/nih-research-matters\/accurate-blood-test-alzheimer-s-disease<\/a><\/p>\n\n\n\nhttps:\/\/www.medicalnewstoday.com\/articles\/new-blood-test-may-help-diagnose-show-how-far-alzheimers-progressed<\/a><\/p>\n\n\n\nMedications that have been suggested by doctors worldwide are available on below link<\/p>\n\n\n\n